Here is some info on ADVR... A profile from Yahoo:http://biz.yahoo.com/p/a/advr.ob.html
Rumors are at the bottom of this post...
Last 2 substantive NRs:
Advanced Viral Research Corp. (OTCBB:ADVR) today announced that
Substance R, its non-toxic peptide nucleic acid (PNA) immunomodulator,
has received formal approval for Phase I human clinical studies in
Argentina.
Substance R (Panar 097, Reticulose(TM)), is a non-toxic peptide nucleic
acid being developed by the company as a broad spectrum antiviral drug.
The drug shows promise for the treatment of viral infections such as
AIDS and Human Papilloma Virus (HPV), and autoimmune diseases like
rheumatoid arthritis and diabetes mellitus. Peptide nucleic acids are
stable analogues of genes and have applications as genomics. Advanced
Viral Research Corp. laboratory studies have shown that Substance R
inhibits the production of both the CCR5 and CXCR4 chemokine receptors,
the key cellular co-receptors for the human immunodeficiency virus
(HIV).
"The approval of human trials in Argentina is a very important step on
the road to making Substance R available for clinical use worldwide,"
said Shalom Z. Hirschman, M.D., President and Chief Executive Officer
of Advanced Viral Research Corp. "Working with our scientific
colleagues in Argentina, we have successfully laid the groundwork to
move our application through ANMAT (the Administracion Nacional de
Medicamentos, Alimentos y Tecnologia Medica -- National Administration
for Drug, Food and Medical Technology), so that we may market Substance
R in their country, helping to alleviate the suffering of people with a
variety of debilitating diseases. I am especially gratified that the
clinical approvals are progressing as planned in Argentina while we
prepare our applications to the FDA in the United States," Dr.
Hirschman stated.
Clinical trials in patients with AIDS and HPV (the cause of genital
warts and a critical factor in the development of cervical cancer) are
planned in Argentina. The approval for human clinical tests in
Argentina also paves the way for future study of the therapeutic
effects of Substance R in other important diseases, such as rheumatoid
arthritis and diabetes mellitus.
Substance R is a second-generation therapeutic. Its predecessor was
developed in the early 1900s. Using modern medical technology,
scientists at The Advanced Viral Research Institute have refined the
PNA preparation and pharmaceutical production, making today's Substance
R a truly novel drug.
About The Advanced Viral Research Institute
Advanced Viral Research Corp.'s foundation begins with a dedication
to scientific research and cutting-edge innovation. In that spirit, the
company created The Advanced Viral Research Institute to foster
individual scientific inquiry and creativity. Here, a respected team of
molecular biologists, immunologists and other scientists conduct
biomedical research in an academically oriented environment. Recent
successes include identifying Substance R's mechanism of action, which
will help with the company's planned Investigational New Drug (IND)
application to the FDA. The Advanced Viral Research Institute also is
developing other PNA-based therapeutics.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm committed to researching, developing and
bringing to market new, effective therapies for viral and other
diseases, which will lead to the alleviation of human suffering and
diseases worldwide. Its flagship drug, Substance R (Reticulose(TM)), is
a non-toxic immunomodulator that has been shown to have beneficial
therapeutic effects against viral diseases such as AIDS.
NR of 17 Nov 99:
MCLEAN, Va.--(BW HealthWire)--Nov. 17, 1999--Shalom Z. Hirschman,
M.D., President and CEO of Advanced Viral Research Corp. (OTCBB:ADVR),
reported yesterday that the experimental drug, Substance R
(Reticulose(TM)), appears to "turn on" the body's beneficial response
to fight viral infections, including HIV (human immunodeficiency
virus) and HPV (human papilloma virus). Advanced Viral Research Corp.
is developing Substance R, a non-toxic peptide-nucleic acid, as a
broad spectrum antiviral drug.
Speaking at a Cambridge HealthTech Institute conference on
chemokines and chemokine receptors -- proteins that play an important
role in trafficking immune system function -- Dr. Hirschman, an
internationally-recognized authority in infectious diseases, presented
case studies of two AIDS patients treated with Substance R. Both
patients were initially unable to tolerate the AIDS cocktail called
HAART (highly active antiretroviral therapy). When treated with a
combination of Substance R and HAART, however, both experienced a
dramatic drop in viral load, increases in weight and CD4 positive cell
count, and an improved quality of life.
"Clinical results of the therapeutic efficacy of Substance R
combined with HAART are very encouraging," said Dr. Hirschman. He
cautioned against regarding Substance R as a "magic bullet," but
expressed optimism about research findings to date.
Substance R Case Studies
Two patients were treated with Substance R combined with a HAART
drug cocktail of azidothymidine (AZT), lamivudine, a protease
inhibitor and nevirapine. Prior to combination therapy, both patients
did not tolerate the cocktail treatment alone. Moreover, while solely
on HAART, both experienced increases in viral load.
At the beginning of combination therapy, "Patient P" had a high
viral load, a low CD4 positive cell count and weighed only 70 pounds.
After three months on Substance R plus HAART, however, his viral load
was undetectable. This patient felt so well that he discontinued
treatment on his own, and his viral load increased. When he resumed
treatment, his viral load again became undetectable and has remained
so for over a year. "Patient P's" CD4 positive count is now about 130
cells per microliter.
"Patient N" began treatment with a high viral load and a CD4
positive cell count of only 50 per microliter. He weighed less than
100 pounds. After combination therapy, he weighs more than 200 pounds,
his viral load is undetectable, and his CD4 positive cell count is
greater than 400 per microliter.
Substance R + Cytokine, Chemokine Stimulation
Dr. Hirschman also presented data from experiments conducted at
the company's Advanced Viral Research Institute, indicating that
Substance R stimulates several chemokines, including interferon gamma
and interleukin-8. Research also showed that Substance R interferes
with viral replication and that it decreases production of CCR5 and
CXCR4, the two co-receptors required for HIV attachment to cells.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm committed to researching, developing and
bringing to market new, effective therapies for viral and other
diseases, which will lead to the alleviation of human suffering and
diseases worldwide. Its flagship drug, Substance R (Reticulose(TM)),
is a non-toxic immunomodulator that has been shown to have beneficial
therapeutic effects against viral diseases such as AIDS.
There is a RUMOR that ADVR is very close to announcing FDA trials... remember... RUMOR... this does NOT MEAN THAT I SAID IT WOULD HAPPEN.
Tom |
